Navigation Links
VirtualScopics Reports Dr. Mostafa Analoui Elected Chairman of the Board
Date:8/16/2013

ROCHESTER, N.Y., Aug. 16, 2013 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ:   VSCP), a leading provider of quantitative imaging, today announced that Dr. Mostafa Analoui was elected chairman of the board.  Dr. Analoui has served as a board member for five years and is currently the Head of Healthcare and Life Sciences Division at the Livingston Group in New York City. Prior to that, Dr. Analoui was a Senior Director and the Groton/New London Site Head for Global Clinical Technology at Pfizer Global Research and Development from 2001 through February 2008, where he led the platform technology mission for the clinical development and commercial division in areas including the medical imaging, diagnostics computational medicine, knowledge management and non-invasive measurement monitoring.

"VirtualScopics is a major player in the imaging CRO market, built around unique and broad tools, processes, and talents to address significant needs in clinical trials for therapeutics and medical devices.  I am excited and honored to be trusted by my colleagues to lead the board as the company goes through a critical path to recovery and planning for strong growth in our core business," said Dr. Analoui. He further stated, "In recognition of company's recent decline in revenue and slow progress in the personalized medicine initiative, the board recently created a task force to review and offer recommendations for our business lines, as well as improvements in board governance. The Board has received and endorsed recommendations from the task force and intends to be actively engaged in the development of the strategic plans and the implementation of these recommendations."

Dr. Analoui expressed his appreciation to outgoing Board Chair Robert Klimasewski, saying, "Bob has been an integral part of VirtualScop
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VirtualScopics Reports Second Quarter 2013 Results
2. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
3. VirtualScopics Reports First Quarter 2013 Results
4. VirtualScopics Receives Additional Time to Regain Compliance with Nasdaq
5. VirtualScopics Reports Fourth-Quarter and Full-Year 2012 Results
6. VirtualScopics Schedules Fourth Quarter and Full Year 2012 Earnings Announcement
7. VirtualScopics Reports 3rd Quarter 2012 Results
8. VirtualScopics Receives Issuance of Influential Patent in Canada
9. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
10. VirtualScopics Announces Receipt of Notice from Nasdaq
11. VirtualScopics Reports 2nd Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Quarter 2011 2011 Fourth Quarter Total Revenue $688.5 million; ... forma organic growth, excluding the impact of foreign exchange and acquisitions, was 10% ... 2011 Fourth Quarter GAAP Operating Cash Flow $190 million; Adjusted Operating ... Total 2011 revenue was $2.46 billion ...
... Inc., (NASDAQ: DCTH ) announced today that ... the Delcath Hepatic CHEMOSAT ® Delivery System at ... treatment and research center located in Frankfurt. The cases were ... agreement the Company announced with the hospital in December ...
Cached Medicine Technology:Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 2Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 3Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 4Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 5Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 6Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 7Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 8Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 9Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 10Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 11Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 12Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 13Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 14Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 15Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 16Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 17Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 18Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 19Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
... Aggression, testosterone and nepotism dont necessarily help one climb ... female can, according to new research on the social ... The study, published today in the journal Proceedings of ... status, reproductive physiology and group dynamics. , ...
... Hopkins researchers question government decision to lower requirements ... -- Challenging a recent U.S. government decision to ... heart transplant hospital, a new Johns Hopkins Medical ... from 10 transplants to 14 transplants a year. ...
... new study from the Monell Center increases understanding ... and vomiting that often afflict patients undergoing chemotherapy. ... new approaches to combat these debilitating side effects. ... nausea and vomiting that accompany chemotherapy treatment, we ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... 2008 Preventative heart healthcare gains strong momentum today ... involvement as the exclusive radiology provider for the High-Risk ... joint research effort to advance the understanding and management ... primary underlying cause of heart attacks and strokes. ...
... to Nutrition on the Go, an,innovative new program from Diet.com, ... 1,700 restaurants nationwide is available in,a flash through your cell ... item., Not cell phone savvy? No worries. You put ... you need help with, then send that info to,DIET1 (34381). ...
Cached Medicine News:Health News:Females decide whether ambitious males float or flounder 2Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: